Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 277

1.

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF.

Gastroenterology. 2007 Jan;132(1):52-65. Epub 2006 Nov 29.

PMID:
17241859
[PubMed - indexed for MEDLINE]
2.

Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.

Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM.

Am J Gastroenterol. 2009 May;104(5):1170-9. doi: 10.1038/ajg.2009.59. Epub 2009 Apr 7.

PMID:
19352339
[PubMed - indexed for MEDLINE]
3.

Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics.

Sandborn WJ, Colombel JF, Schreiber S, Plevy SE, Pollack PF, Robinson AM, Chao J, Mulani P.

Inflamm Bowel Dis. 2011 Jan;17(1):141-51. doi: 10.1002/ibd.21328.

PMID:
20848500
[PubMed - indexed for MEDLINE]
4.

Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.

Sandborn WJ, Colombel JF, D'Haens G, Plevy SE, Panés J, Robinson AM, Pollack PF, Zhou Q, Castillo M, Thakkar RB.

Curr Med Res Opin. 2013 May;29(5):483-93. doi: 10.1185/03007995.2013.779575. Epub 2013 Mar 14.

PMID:
23438483
[PubMed - indexed for MEDLINE]
5.

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.

Panaccione R, Colombel JF, Sandborn WJ, Rutgeerts P, D'Haens GR, Robinson AM, Chao J, Mulani PM, Pollack PF.

Aliment Pharmacol Ther. 2010 Jun;31(12):1296-309. doi: 10.1111/j.1365-2036.2010.04304.x. Epub 2010 Mar 18.

PMID:
20298496
[PubMed - indexed for MEDLINE]
6.

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF.

Gut. 2007 Sep;56(9):1232-9. Epub 2007 Feb 13.

PMID:
17299059
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.

Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF.

Ann Intern Med. 2007 Jun 19;146(12):829-38. Epub 2007 Apr 30.

PMID:
17470824
[PubMed - indexed for MEDLINE]
8.

Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease.

Watanabe M, Hibi T, Lomax KG, Paulson SK, Chao J, Alam MS, Camez A; Study Investigators.

J Crohns Colitis. 2012 Mar;6(2):160-73. doi: 10.1016/j.crohns.2011.07.013. Epub 2011 Aug 26.

PMID:
22325170
[PubMed - indexed for MEDLINE]
9.

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.

Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.

Am J Gastroenterol. 2008 Dec;103(12):3132-41. doi: 10.1111/j.1572-0241.2008.02175.x. Epub 2008 Oct 3. Erratum in: Am J Gastroenterol. 2009 Jul;104(7):1894.

PMID:
18853973
[PubMed - indexed for MEDLINE]
10.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120
[PubMed - indexed for MEDLINE]
11.
12.

Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.

Panaccione R, Loftus EV Jr, Binion D, McHugh K, Alam S, Chen N, Guerette B, Mulani P, Chao J.

Can J Gastroenterol. 2011 Aug;25(8):419-25.

PMID:
21912766
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.

Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W; EXTEND Investigators, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G.

Gastroenterology. 2012 May;142(5):1102-1111.e2. doi: 10.1053/j.gastro.2012.01.035. Epub 2012 Feb 8.

PMID:
22326435
[PubMed - indexed for MEDLINE]
14.

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P.

Gastroenterology. 2006 Feb;130(2):323-33; quiz 591.

PMID:
16472588
[PubMed - indexed for MEDLINE]
15.

Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.

Viola F, Civitelli F, Di Nardo G, Barbato MB, Borrelli O, Oliva S, Conte F, Cucchiara S.

Am J Gastroenterol. 2009 Oct;104(10):2566-71. doi: 10.1038/ajg.2009.372. Epub 2009 Jun 23.

PMID:
19550415
[PubMed - indexed for MEDLINE]
16.

Adalimumab: in Crohn's disease.

Plosker GL, Lyseng-Williamson KA.

BioDrugs. 2007;21(2):125-32; discussion 133-4. Review.

PMID:
17402796
[PubMed - indexed for MEDLINE]
17.

Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial.

Rubin DT, Mulani P, Chao J, Pollack PF, Bensimon AG, Yu AP, Ghosh S.

Inflamm Bowel Dis. 2012 May;18(5):818-25. doi: 10.1002/ibd.21836. Epub 2011 Sep 1.

PMID:
21887727
[PubMed - indexed for MEDLINE]
18.

Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.

Loftus EV Jr, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM.

Eur J Gastroenterol Hepatol. 2009 Nov;21(11):1302-9. doi: 10.1097/MEG.0b013e32832a8d71.

PMID:
19465858
[PubMed - indexed for MEDLINE]
19.

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C.

Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060. Review.

PMID:
21291629
[PubMed - indexed for MEDLINE]
Free Article
20.

Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.

Peyrin-Biroulet L, Laclotte C, Bigard MA.

Aliment Pharmacol Ther. 2007 Mar 15;25(6):675-80.

PMID:
17311600
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk